To investigate the effects of cell-specific alteration of Slc11a2 in AD, we generated a novel model of tamoxifen-inducible, microglial-specific knockdown of Slc11a2 in the APP/PS1 mouse model of AD. Here, SLC11A2 is linked to Alzheimer disease.